Study identifier:D6995C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open, multicentre Phase I clinical study to assess the tolerability of fulvestrant 500 mg in postmenopausal women with hormone receptor positive advanced or recurrent breast cancer
Advanced breast cancer
Phase 1
No
Fulvestrant
Female
20
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer
Location
Location
Tokyo, Japan
Location
Nagoyata, Japan
Location
Chiba, Japan
Location
Osaka, Japan
Location
Fukuoka, Japan
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.